The U.S. FDA has given the green light to Biocon Biologics' biosimilar YESINTEK™, Bmab 1200, which is comparable to J&J's Stelara® (Ustekinumab).

Alector reveals findings from the AL002 INVOKE-2 Phase 2 study on early Alzheimer’s disease and shares company updates.

Tenaya Therapeutics has administered the first dose to a patient in the Phase 1b clinical study of TN-401, part of the RIDGE™-1 trial, aimed at treating ARRVC linked to PKP2.

Novartis' Kisqali® has secured approval from the European Commission for use in a wide range of patients with HR+/HER2- early breast cancer who are at high risk of recurrence.

Hanmi Pharmaceutical and Beijing Hanmi are advancing clinical trials for BH3120, a co-developed next-gen cancer immunotherapy.

Biohaven Offers Update on Taldefgrobep Alfa Development for Spinal Muscular Atrophy and Obesity.

GC Biopharma and Novel Pharma have started a global Phase I clinical trial for treating MPS IIIA, with the first patient now dosed.

Amgen reports significant weight loss with maritide in individuals with obesity or excess weight after 52 weeks in a phase 2 trial.

PTC Therapeutics' Phase 2 ALS Trial Fails Main Objective.

SCG Cell Therapy showcased encouraging Phase 1 results for its new HBV-targeted TCR-T treatment (SCG101) during the AASLD Liver Meeting 2024.

Brenig Therapeutics has launched its first human clinical trial for BT-267, a leading LRRK2 inhibitor targeting Parkinson's Disease.

Avirmax Biopharma has initiated its clinical trial for ABI-110, a novel gene therapy targeting Wet AMD and PCV, with the first patient receiving treatment.